About Algynomics

The Algynomics team includes internationally renowned scientists with extensive experience researching the pathophysiology of pain and associated conditions. Our expertise lies in the study of pain genetics, quantitative neurosensory and pain measurement, clinical trial design and conduct, and associated analyses.

Algynomics has access, through direct ownership and licensing, to data and biological samples from large collections of patient cohorts with persistent pain and related conditions. These cohorts are fully characterized phenotypically and genotypically to enable in-depth analyses of pain pathways and response to treatment.

With a larger mission of relieving human pain conditions with new discoveries and technologies that will lead to personalized pain therapies, diagnostics and new pharmacological treatments, Algynomics prides itself on bringing discoveries from academic and industry research to practice or to patient care.

www.algynomics.com

Algynomics, Inc.
208 N. Columbia St.
Chapel Hill, NC 27514

Phone 919.261.7886
Fax   919.287.2924
Email   info@algynomics.com

Algynomics

Personalized
Pain Medications
& Diagnostics

Algynomics

For Pharma

The unique expertise of the Algynomics team in the fields of clinical pain and pain genetics enables us to provide early and late stage clinical services including:

- Evaluating responses to pain therapy to minimize placebo effects, appropriately targeting and stratifying study populations and co-developing diagnostic screening tools to improve patent profiling and subsequent response to treatment.

- Identifying new therapeutic targets through use of our proprietary Pain Research Panel and/or through genome-wide scans.

- Designing clinical trials for pain and associated conditions to ensure thorough phenotypic and genotypic characterization of cohorts and appropriate outcomes assessment.

- Using genetic and phenotypic measures to reassess data from failed Phase II/Phase III clinical trials.

For Researchers

Clinical Services: Algynomics is able to evaluate genomic and phenotypic patient data, and/or partner with researchers to use their clinical data for translational/ industry application by:

- Designing hypothesis-driven studies with thorough phenotypic and genotypic characterization of cohorts and appropriate outcomes assessment.

- Facilitating statistical analysis of clinical datasets containing phenotypic and genotypic data.

- Applying and analyzing data derived from the Algynomics' Pain Research Panel.

- Helping to bring data and ideas to market, and serving as the "translational arm" for researchers' academic activities.

Pre-clinical Services: Algynomics offers an array of behavioral screening assays, biological tissues and fluids collected from control and experimental animals.

Pain Research Panel

Algynomics' Pain Research Panel is a custom chip based on an Illumina iSelect chip using Illumina's Infinium platform. It contains more than 5,300 SNPs representing over 540 genes implicated in pain perception, inflammation, and mood. The Pain Research Panel allows investigators to analyze genetic factors associated with clinical pain states using existing analyses and technologies that were developed for this purpose. These analyses allow researchers to better understand the pathophysiology of pain conditions and identify valuable clinical biomarkers.

For consultation regarding project development and use of the Pain Panel, please contact Dr. Inna Belfer at **412.648.1342**; ibelfer@algynomics.com

For technical questions about the Pain Research Panel, please contact Dr. Shad Smith at **919.698.5346**; ssmith@algynomics.com